Undisclosed ADC therapeutic / Biocytogen, Myricx Pharma - LARVOL DELTA

Francis Crick and ICL spinout raises £90m to clinically develop cancer treatments (PharmaTimes) - "The Francis Crick Institute and Imperial College London (ICL) cancer therapy spinout, Myricx Bio, has raised £90m in series A financing to advance its novel cancer treatments into clinical development...The investment will help to develop the company’s therapies to treat a range of different tumour types, including breast, lung and colorectal cancer, to advance into clinical testing...The spinout is focused on the discovery and development of a novel class of payloads for antibody-drug conjugates..."

Financing • Breast Cancer • Colorectal Cancer • Lung Cancer

Biocytogen Enters into Antibody Evaluation, Option and License Agreement with Myricx for ADC Development (Businesswire) - "Biocytogen Pharmaceuticals...today announces an antibody evaluation, option and license agreement with Myricx Bio (‘Myricx’), a UK biotech company focusing on the discovery and development of a completely novel class of selective cytotoxic payloads for antibody drug conjugates (ADCs). Under the terms of the agreement, Myricx will provide its proprietary linker and payload and Biocytogen will conjugate them with its RenMice®-derived fully human antibodies to make ADCs. Biocytogen will carry out feasibility tests for these ADCs as CRO services, and upon option exercise, Myricx will be responsible for further development and commercialization. Biocytogen will receive an upfront payment and, subject to exercise Biocytogen will be eligible to receive ongoing development and commercialisation milestone payments, as well as single-digit royalties on net sales."

Licensing / partnership • Oncology